- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT06106828
A satralizumab hatékonyságának, biztonságosságának, farmakokinetikájának és farmakodinámiájának értékelése pajzsmirigy-szembetegségben szenvedő betegeknél (SatraGO-2) (SatraGO-2)
III. fázisú, randomizált, kettős maszkos, placebo-kontrollos, többközpontú vizsgálat a satralizumab hatékonyságának, biztonságosságának, farmakokinetikájának és farmakodinámiájának értékelésére közepesen súlyos vagy súlyos pajzsmirigy-szembetegségben szenvedő betegeknél
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Seongnam-si, Dél -Korea, 13620
- Seoul National University Bundang Hospital
-
Seoul, Dél -Korea, 003-722
- Severance Hospital, Yonsei University Health System
-
Seoul, Dél -Korea, 135-710
- Samsung Medical Center
-
Seoul, Dél -Korea, 06973
- Chung-Ang University Hospital
-
-
-
-
-
Brighton, Egyesült Királyság, BN2 5BF
- Sussex Eye Hospital
-
Bristol, Egyesült Királyság, BS1 2LX
- Bristol Eye Hospital
-
Glasgow, Egyesült Királyság, G12 0YN
- Gartnavel General Hospital
-
Leeds, Egyesült Királyság, LS9 7TF
- St James University Hospital
-
Liverpool, Egyesült Királyság, L7 8XP
- Royal Liverpool University Hospital
-
London, Egyesült Királyság, EC1V 2PD
- Moorfields Eye Hospital NHS Foundation Trust
-
Maidstone, Kent, Egyesült Királyság, ME16 9QQ
- Maidstone Hospital
-
-
-
-
California
-
San Diego, California, Egyesült Államok, 92108
- Plastics-Orbit-Neuro
-
-
Connecticut
-
Danbury, Connecticut, Egyesült Államok, 06810
- Connecticut Eye Consultants, P.C.
-
-
Illinois
-
Chicago, Illinois, Egyesült Államok, 60612
- University of Illinois Eye and Ear Infirmary
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104
- Scheie Eye Institute
-
-
Tennessee
-
Nashville, Tennessee, Egyesült Államok, 37232-8808
- Vanderbilt Eye Institute
-
-
Texas
-
San Antonio, Texas, Egyesült Államok, 78251
- Retina Consultants of Texas
-
-
-
-
-
Nantes, Franciaország, 44093
- CHU Nantes - Hôtel Dieu
-
Paris, Franciaország, 75019
- Fondation Rothschild
-
Paris, Franciaország, 75012
- CHNO Hopital des Quinze Vingts
-
-
-
-
-
Jerusalem, Izrael, 9112001
- Hadassah MC
-
Petah Tikva, Izrael, 4941492
- Rabin MC
-
Ramat Gan, Izrael
- Sheba medical center
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada
- University of Alberta
-
-
Ontario
-
Toronto, Ontario, Kanada, M3C 0G9
- Toronto Retina Institute
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 2M4
- Universite de Montreal - Hopital Maisonneuve-Rosemont
-
-
-
-
-
Beijing, Kína, 100191
- Peking University Third Hospital
-
Beijing, Kína, 100032
- Peking Union Medical College Hospital
-
Beijing, Kína, 100730
- Beijing Hospital of Ministry of Health
-
Beijing, Kína, 100730
- Beijing Tongren Hospital, Capital Medical University
-
Xi'an, Kína, 710004
- Xi'an Fourth Hospital
-
-
-
-
-
Bydgoszcz, Lengyelország, 85-316
- Specjalistyczny Osrodek Okulistyczny Oculomedica
-
Gdansk, Lengyelország, 80-180
- Profesorskie Centrum Medyczne Spolka Z Ograniczona Odpowiedzialnoscia
-
-
-
-
-
Coimbra, Portugália, 3000-548
- AIBILI - Association for Innovation and Biomedical Research on Light
-
-
-
-
-
Barcelona, Spanyolország, 08035
- Hospital Universitario Vall D hebron
-
Granada, Spanyolország, 18012
- Hospital Universitario Virgen de las Nieves
-
Madrid, Spanyolország, 28040
- Hospital Universitario Clinico San Carlos
-
Madrid, Spanyolország, 28031
- Hospital Ramon y Cajal
-
Seville, Spanyolország, 41007
- Hospital Universitario Virgen De La Macarena
-
Valencia, Spanyolország, 46026
- Hospital Universitario la Fe: Servicio de Oftalmologia
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanyolország, 8907
- Hospital Universitari de Bellvitge
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Bevételi kritériumok:
- A pajzsmirigy-szembetegség (TED) klinikai diagnózisa CAS alapján
Kizárási kritériumok:
- A CAS vagy a proptosis csökkenése >= 2 ponttal, illetve >= 2 mm-rel a vizsgált szemben a szűrés és a vizsgálati alapvonal között (1. nap)
- Azonnali sebészeti szemészeti beavatkozást igényel, vagy korrekciós műtétet vagy besugárzást tervez a vizsgálat során, a vizsgáló megítélése szerint
- Azonosított, már létező szemészeti betegség, amely a vizsgáló megítélése szerint kizárná a vizsgálatban való részvételt vagy megnehezítené a vizsgálati eredmények értelmezését, beleértve az orvosi kezelésre nem reagáló szaruhártya-dekompenzációt, valamint olyan szemészeti betegségeket, amelyek valószínűleg tiltott terápiát igényelnek a vizsgálat során
- Bármilyen súlyos egészségügyi állapot vagy rendellenesség a klinikai laboratóriumi vizsgálatok során, amely a vizsgáló megítélése szerint kizárja az egyén biztonságos részvételét a vizsgálatban és annak befejezését
- Terhes vagy szoptat, vagy teherbe esni szándékozik a vizsgálat alatt vagy a satralizumab utolsó adagját követő 12 héten belül
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Satralizumab
Az I. részbeni időszakban a résztvevők satralizumabot kapnak 4 hetente (q4w), majd proptózis-válaszon alapuló egyéni kezelést kapnak a vizsgálat II. részében.
|
A satralizumabot szubkután injekció formájában kell beadni.
|
|
Placebo Comparator: Placebo
Az I. rész periódusában a résztvevők négy hétig placebót kapnak, majd a vizsgálat II. részében proptózis-válaszon alapuló, személyre szabott kezelést kapnak.
|
A placebót SC injekció formájában adják be
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Percentage of Participants in the Active TED Population Who Achieved ≥ 2 Millimeters (mm) Reduction in Proptosis From Baseline at Week 24 in the Study Eye
Időkeret: At Week 24
|
Percentage of participants in the active TED population (i.e., participants who have active disease) who achieved a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye have been reported.
Percentages have been rounded off.
|
At Week 24
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Percentage of Participants in Active TED Population Achieving ≥ 1 Grade Reduction/Improvement in Diplopia at Week 24
Időkeret: At Week 24
|
Diplopia grade was assessed with the use of the Gorman subjective diplopia score (range: 0-3 points), which included: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3).
Participants with active TED with diplopia present at baseline who had Grade ≥1 reduction or improvement at Week 24 have been reported.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in the Overall Population Achieving ≥ 1 Grade Reduction/Improvement in Diplopia at Week 24
Időkeret: At Week 24
|
Diplopia grade was assessed with the use of the Gorman subjective diplopia score (range: 0-3 points), which included: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3).
Participants with active and chronic inactive TED with diplopia present at baseline who had Grade ≥1 reduction or improvement at Week 24 have been reported.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population Achieving Absence of Motility-induced Pain at Week 24
Időkeret: At Week 24
|
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population Who Achieved Overall Response in the Study Eye at Week 24
Időkeret: At Week 24
|
Overall Response was defined as a ≥ 2-point reduction in clinical activity score (CAS), and a ≥ 2 mm reduction in proptosis from baseline in the study eye, provided there is no corresponding deterioration in CAS or proptosis (≥ 2-point/mm increase) in the fellow eye.
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population Who Achieved a ≥ 2-point Reduction in CAS in the Study Eye From Baseline to Week 24
Időkeret: At Week 24
|
CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population Who Achieved a CAS Value of 0 or 1 in the Study Eye at Week 24
Időkeret: At Week 24
|
CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
Percentages have been rounded off.
|
At Week 24
|
|
Number of Participants With Adverse Events (AEs)
Időkeret: Up to Week 72
|
An AE is any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
|
Up to Week 72
|
|
Serum Trough Concentration (Ctrough) of Satralizumab at Specified Timepoints
Időkeret: Baseline, Weeks 2, 4, 8, 12 and 24
|
Baseline, Weeks 2, 4, 8, 12 and 24
|
|
|
Percentage of Participants in the Overall Population Who Achieved ≥ 2 mm Reduction in Proptosis From Baseline at Week 24 in the Study Eye
Időkeret: At Week 24
|
Percentage of participants in the overall population (i.e., participants with active and chronic inactive TED) who achieved a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye have been reported.
Percentages have been rounded off.
|
At Week 24
|
|
Change From Baseline in Proptosis at Week 24 in Active TED Population for Study Eye
Időkeret: At Week 24
|
This analysis used a Mixed-effects Model for Repeated Measure (MMRM) model.
Adjusted mean values have been reported here.
|
At Week 24
|
|
Change From Baseline in Proptosis at Week 24 in Overall Population for Study Eye
Időkeret: At Week 24
|
This analysis used a MMRM model.
Adjusted mean values have been reported here.
|
At Week 24
|
|
Percentage of Participants in Active TED Population Achieving Absence of Spontaneous Pain at Week 24
Időkeret: At Week 24
|
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population With a ≥ 6-point Improvement in the Visual Functioning Subscale of the Graves' Ophthalmopathy Quality-of-life (GO-QoL) From Baseline at Week 24
Időkeret: At Week 24
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales, and is used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants in Active TED Population With a ≥ 6-point Improvement in the Appearance Subscale of the GO-QoL From Baseline at Week 24
Időkeret: At Week 24
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants With a ≥ 10-point Improvement in the Ocular Surface Disease Index (OSDI) Overall Scores Across All Levels of Baseline Severity at Week 24 in Overall Population
Időkeret: At Week 24
|
The OSDI instrument is a validated dry eye questionnaire and consists of three main sections concerning ocular symptoms, visual function, and environmental factors.
It comprises of 12 questions and for every question, participants select a number between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time" with totals of score ranging from 0 to 100.
Higher scores represent a worse disease index.
Percentages have been rounded off.
|
At Week 24
|
|
Change From Baseline in the OSDI Ocular Symptoms, and Vision-related Function Subscale Scores at Week 24 in the Overall Population
Időkeret: At Week 24
|
The OSDI instrument is a validated dry eye questionnaire and consists of three main sections concerning ocular symptoms, visual function, and environmental factors.
It comprises of 12 questions and for every question, participants select a number between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time" with totals of score ranging from 0 to 100.
Higher scores represent a worse disease index.
This analysis used a MMRM model.
Adjusted mean values have been reported here.
|
At Week 24
|
|
Change From Baseline in Oxford Corneal Staining Scores at Week 24 in the Overall Population
Időkeret: At Week 24
|
Corneal staining was graded using Oxford Corneal Staining Chart which consists of a 6-point scale.
Staining assessment will be based on the intensity of fluorescein staining, ranging from Grade 0 to V for each panel (0=absent; I=minimal; II=mild; III=moderate; IV= marked; and V=severe).
Higher grade indicates worse disease index.
The observer compares the overall appearance of the participant's corneal staining with the reference figure in the protocol.
The observer selects the appropriate grade that best represents the state of corneal staining.
The staining score were recorded for the exposed interpalpebral cornea and conjunctiva.
This analysis used a MMRM model.
Adjusted mean values have been reported here.
|
At Week 24
|
|
Percentage of Participants Who Achieved Complete Binocular Diplopia Response at Week 24 in Overall Population
Időkeret: At Week 24
|
The percentage of participants achieving a complete binocular diplopia response (diplopia score=0) at Week 24 have been reported.
Diplopia grade was assessed with the use of the Gorman subjective diplopia score (range: 0-3 points), which included: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3).
Percentages have been rounded off.
|
At Week 24
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) Achieving ≥ 2 mm Reduction in Proptosis at Week 48 in the Study Eye
Időkeret: At Week 48
|
Percentage of participants (proptosis non-responders) who will achieve a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 48 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye will be reported.
|
At Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) Achieving Overall Response at Week 48
Időkeret: At Week 48
|
Overall Response is defined as a ≥ 2-point reduction in CAS, and a ≥ 2 mm reduction in proptosis from baseline in the study eye, provided there is no corresponding deterioration in CAS or proptosis ( ≥ 2-point/mm increase) in the fellow eye.
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
At Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) Achieving a ≥ 2-point Reduction in CAS in the Study Eye From Baseline to Week 48
Időkeret: Baseline to Week 48
|
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
Baseline to Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) Achieving Grade ≥ 1 Reduction/Improvement in Diplopia at Week 48 in Participants With Baseline Diplopia > 0
Időkeret: At Week 48
|
Diplopia grade was assessed with the use of the Gorman subjective diplopia score (range: 0-3 points), which included: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3).
|
At Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) With a ≥ 6-point Improvement in the Visual Functioning and Appearance Subscale Scores of the GO-QoL From Week 24 to Week 48
Időkeret: From Week 24 to Week 48
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
|
From Week 24 to Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) With a ≥ 6-point Improvement in the Visual Functioning and Appearance Subscale Scores of the GO-QoL From Baseline to Week 48
Időkeret: From baseline up to Week 48
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
|
From baseline up to Week 48
|
|
Change From Baseline in Proptosis at Week 48 (in Proptosis Non-responders at Week 24)
Időkeret: Baseline and Week 48
|
Proptosis response is defined as achieving a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye.
|
Baseline and Week 48
|
|
Percentage of Participants (Proptosis Non-responders at Week 24) Requiring Surgical Intervention for TED up to Week 48
Időkeret: Up to Week 48
|
Up to Week 48
|
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Worsening of Proptosis by ≥ 2 mm From Week 24 to Week 48
Időkeret: From Week 24 to Week 48
|
From Week 24 to Week 48
|
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Worsening of Proptosis by ≥ 2 mm From Baseline to Week 48
Időkeret: Baseline to Week 48
|
Baseline to Week 48
|
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Maintenance of Proptosis Response From Week 24 at Week 48
Időkeret: Weeks 24 and 48
|
Proptosis response is defined as achieving a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye.
|
Weeks 24 and 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Maintenance of CAS Response From Week 24 at Week 48
Időkeret: Weeks 24 and 48
|
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
Weeks 24 and 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Maintenance of Proptosis Response From Baseline at Week 48
Időkeret: At Week 48
|
Proptosis response is defined as achieving a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye.
|
At Week 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) With Maintenance of CAS Response From Baseline at Week 48
Időkeret: At Week 48
|
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
At Week 48
|
|
Change in Proptosis From Week 24 to 48 (in Proptosis Responders at Week 24)
Időkeret: From Week 24 to Week 48
|
Proptosis response is defined as achieving a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye.
|
From Week 24 to Week 48
|
|
Change in CAS From Week 24 to 48 (in Proptosis Responders at Week 24)
Időkeret: From Week 24 to Week 48
|
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
From Week 24 to Week 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) With a ≥ 6-point Improvement in the Visual Functioning and Appearance Subscale Scores of the GO-QoL From Week 24 to Week 48
Időkeret: From Week 24 to Week 48
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
|
From Week 24 to Week 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) With a ≥ 6-point Improvement in the Visual Functioning and Appearance Subscale Scores of the GO-QoL From Baseline to Week 48
Időkeret: From baseline up to Week 48
|
The GO-QoL is a 16-item self-administered questionnaire divided into two sub-scales and used to assess the perceived effects of TED by the participants on their: 1) Visual Functioning (questions 1-8); and 2) Appearance (questions 9-16).
Both subscales and overall score (sum of scores from all 16 questions) are transformed to a scale of 0 to 100.
Higher total scores indicate better QoL.
|
From baseline up to Week 48
|
|
Change From Baseline in Proptosis to Week 48 (in Proptosis Responders at Week 24)
Időkeret: Baseline to Week 48
|
Proptosis response is defined as achieving a ≥ 2 mm reduction in proptosis from baseline (Day 1) to Week 24 in the study eye, with no corresponding deterioration of proptosis (≥ 2 mm increase) in the fellow eye.
|
Baseline to Week 48
|
|
Change From Baseline in CAS to Week 48 (in Proptosis Responders at Week 24)
Időkeret: Baseline to Week 48
|
The CAS is a 7-item description of clinical activity, including: 1. Spontaneous orbital pain; 2. Gaze evoked orbital pain; 3. Eyelid swelling that is considered to be due to TED; 4. Eyelid erythema; 5. Conjunctival redness that is considered to be due to active TED (ignore "equivocal" redness); 6. Chemosis; 7. Swelling of caruncle or plica.
Each item is scored as 1 (present) or 0 (absent) and scores for each item are summed for total score of 0 (no inflammatory symptoms) to 7 (most inflammatory symptoms).
Higher scores indicate worse symptoms.
|
Baseline to Week 48
|
|
Percentage of Participants (Proptosis Responders at Week 24) Requiring Surgical Intervention for TED up to Week 48
Időkeret: Up to Week 48
|
Up to Week 48
|
|
|
Number of Participants With Anti-drug Antibodies (ADAs) to Satralizumab at Baseline and During the Study
Időkeret: Up to Week 48
|
Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
|
Up to Week 48
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi igazgató: Clinical Trials, Hoffmann-La Roche
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Endokrin rendszer betegségei
- Genetikai betegségek, veleszületett
- Autoimmun betegség
- Immunrendszeri betegségek
- Szembetegségek
- Szembetegségek, örökletes
- Graves-betegség
- Exophthalmos
- Orbitális betegségek
- Golyva
- Pajzsmirigy túlműködés
- Pajzsmirigy betegségek
- Veleszületett, örökletes és újszülöttkori betegségek és rendellenességek
- Graves Ophthalmopathia
- satralizumab
Egyéb vizsgálati azonosító számok
- GP44729
- 2023-503669-50-00 (Ctis: EU CT Number)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
A képesített kutatók hozzáférést kérhetnek az egyéni páciensszintű adatokhoz a kérési platformon (www.vivli.org) keresztül. További részletek a Roche támogatható tanulmányokra vonatkozó kritériumairól itt találhatók (https://vivli.org/ourmember/roche/).
A Roche klinikai információk megosztására vonatkozó globális politikájával és a kapcsolódó klinikai vizsgálati dokumentumokhoz való hozzáférés kérésével kapcsolatos további részletekért lásd itt (https://www.roche.com/innovation/process/clinical-trials/data-sharing/) .
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .